HEARTMATE 3™ LEFT VENTRICULAR ASSIST SYSTEM
A New Milestone in LVAD Therapy
Introducing the new
HEARTMATE 3™ LVAD WITH FULL MAGLEV™ FLOW TECHNOLOGY

HeartMate 3™ LVAD with Full MagLev™ Flow Technology delivers better blood handling through meaningful innovation.***1
The HeartMate 3™ LVAD with Full MagLev™ Flow Technology sets a new standard of LVAD performance by significantly improving the hemocompatibility-related adverse event (HRAE) profile.

**IMPROVED HRAE PROFILE**

0% PUMP THROMBOSIS

At the 6-month primary endpoint in the MOMENTUM 3 trial.¹

The HeartMate 3™ LVAD addresses the complex interconnectivity of hemocompatibility events by minimizing pump thrombosis without significantly impacting stroke or gastrointestinal bleeding.

**EXCELLENT 6-MONTH SURVIVAL**

89%

¹There is no significant difference between the HeartMate 3 and HeartMate II LVADs with regard to stroke or gastrointestinal bleeding in the MOMENTUM 3 study: 7.9% and 15.9% for the HeartMate 3 LVAD, respectively, vs 10.9% and 15.2% for the HeartMate II™ LVAD in the MOMENTUM 3 trial at 6 months.¹
Meaningful innovation driven by
FULL MAGLEV™ FLOW TECHNOLOGY

Full MagLev™ Flow Technology is designed to provide better blood handling to minimize complications.

UNIQUE HEMODYNAMIC ELEMENTS

- Frictionless design, with the absence of mechanical bearings, may help to eliminate friction, heat buildup and the potential for thrombus
- Wide blood flow pathways intended to minimize hemolysis, blood shearing and stasis
- Intrinsic pulsatility to enable pump washing and help minimize areas of stasis in the pump

DESIGNED TO DELIVER

MINIMAL PUMP THROMBOSIS¹
LOW HEMOLYSIS¹
REDUCED BLOOD SHEARING AND STASIS³

SINTERED TITANIUM SURFACES

Designed to promote hemocompatibility on blood contacting surfaces inside the pump, generating a hemocompatible surface layer that can reduce the potential for thrombus formation.
FEATURING LEVITATING SELF-CENTERING ROTOR

Rotor self-diagnostics are performed tens of thousands of times per second to ensure consistent centering. HeartMate 3™ LVAD rotor will remain suspended and centered, regardless of its orientation, even at zero speed.
MAKING A REAL DIFFERENCE in patients’ lives

**SIGNIFICANT IMPROVEMENT IN NYHA CLASS**

77% PATIENTS IMPROVED to NYHA Class I or II from NYHA Class III or IV (n = 127) at 6 months (p < 0.0001 compared to baseline)

**SIGNIFICANT IMPROVEMENT IN 6-MINUTE WALK DISTANCE**

Average 6-minute walk distance in patients implanted with the HeartMate 3™ LVAD (n = 114) (P < 0.001 compared to baseline)

Note: One football field = 91 m (100 yards)

80% INCREASE IN DISTANCE

164 m (approx. 180 yards)

296 m (approx. 324 yards)

Note: One football field = 91 m (100 yards)
MEANINGFUL IMPROVEMENT IN QUALITY OF LIFE

Kansas City Cardiomyopathy Questionnaire Overall Score Increase from Baseline

68% IMPROVEMENT in mean KCCQ score (standard QoL scale) from baseline

ADVERSE EVENT PROFILE

Adverse events through six months for patients implanted with the HeartMate III LVAD (n = 151).

<table>
<thead>
<tr>
<th>Event</th>
<th>Count</th>
<th>%</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Device thrombosis</td>
<td>0</td>
<td>0%</td>
<td>0</td>
</tr>
<tr>
<td>Hemolysis not associated with pump thrombosis</td>
<td>1</td>
<td>0.7%</td>
<td>1</td>
</tr>
<tr>
<td>GI bleeding</td>
<td>24</td>
<td>15.9%</td>
<td>47</td>
</tr>
<tr>
<td>Stroke*</td>
<td>12</td>
<td>7.9%</td>
<td>12</td>
</tr>
<tr>
<td>Ischemic</td>
<td>8</td>
<td>5.3%</td>
<td>8</td>
</tr>
<tr>
<td>Hemorrhagic</td>
<td>4</td>
<td>2.6%</td>
<td>4</td>
</tr>
<tr>
<td>Bleeding requiring surgery</td>
<td>15</td>
<td>9.9%</td>
<td>15</td>
</tr>
<tr>
<td>Device malfunction requiring reoperation</td>
<td>1</td>
<td>0.7%</td>
<td>1</td>
</tr>
<tr>
<td>Driveline infection</td>
<td>18</td>
<td>11.9%</td>
<td>21</td>
</tr>
<tr>
<td>RVAD usage</td>
<td>4</td>
<td>2.6%</td>
<td>4</td>
</tr>
</tbody>
</table>
A BETTER EXPERIENCE for clinicians and patients

Abbott continues to set new standards with the world’s most comprehensive portfolio of innovative, evidence-based solutions for heart failure therapy supported by a deep commitment to the success of your heart failure program.

- Offers up to 17 hours of battery life for greater patient confidence and convenience
- Designed for intrapericardial placement
- Features a thin, mechanical apical cuff lock for quick and easy pump attachment
- Incorporates a modular driveline that facilitates simple replacement of externalized portion

TO LEARN MORE about the HeartMate 3™ LVAD with Full MagLev® Flow Technology, please contact your Abbott representative or visit www.HeartMate3.com.

EMPOWERING THE TRANSFORMATION OF HEART FAILURE

From treatment to ongoing patient management, Abbott is committed to working with you to transform heart failure and improve more patient lives.

**The HeartMate 3™ LVAS**